Literature DB >> 18785850

Take control over your fluconazole prescriptions: the growing importance of Candida glabrata as an agent of candidemia in Brazil.

Alessandro C Pasqualotto, Ricardo A Zimerman, Sydney H Alves, Valerio R Aquino, Daniela Branco, Denusa Wiltgen, Angelica do Amaral, Raquel Cechinel, Soraya M Colares, Ivana G da Rocha, Luiz Carlos Severo, Teresa Cristina T Sukiennik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18785850     DOI： 10.1086/590191

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


× No keyword cloud information.
  12 in total

1.  In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay.

Authors:  Ana Carolina Azevedo; Fernando César Bizerra; Daniel Arquimedes da Matta; Leila Paula de Almeida; Robert Rosas; Arnaldo Lopes Colombo
Journal:  Mycopathologia       Date:  2010-12-23       Impact factor: 2.574

Review 2.  Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.

Authors:  Kevin Watt; Paolo Manzoni; Michael Cohen-Wolkowiez; Stefano Rizzollo; Elena Boano; Evelyne Jacqz-Aigrain; Daniel K Benjamin
Journal:  Curr Drug Metab       Date:  2013-02       Impact factor: 3.731

3.  National surveillance of fungemia in Denmark (2004 to 2009).

Authors:  Maiken Cavling Arendrup; Brita Bruun; Jens Jørgen Christensen; Kurt Fuursted; Helle Krogh Johansen; Poul Kjaeldgaard; Jenny Dahl Knudsen; Lise Kristensen; Jens Møller; Lene Nielsen; Flemming Schønning Rosenvinge; Bent Røder; Henrik Carl Schønheyder; Marianne K Thomsen; Kjeld Truberg
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

4.  Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil.

Authors:  Marcos Paulo Wille; Thaís Guimarães; Guilherme Henrique Campos Furtado; Arnaldo Lopes Colombo
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

5.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

Authors:  M A Pfaller; S A Messer; R J Hollis; L Boyken; S Tendolkar; J Kroeger; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-08-05       Impact factor: 5.948

6.  Nosocomial bloodstream Candida infections in a tertiary-care hospital in South Brazil: a 4-year survey.

Authors:  Viviane Gevezier da Costa; Regina Mariuza Borsato Quesada; Aline Tancler Stipp Abe; Luciana Furlaneto-Maia; Márcia Cristina Furlaneto
Journal:  Mycopathologia       Date:  2014-08-08       Impact factor: 2.574

7.  Drug susceptibility in emerging fungal infections: tests with fluconazole, itraconazole, and amphotericin B.

Authors:  Vanessa da Silva Fay; Diana Mara Garcia Rodrigues; Stela Maris Bottin Gonçalves; Tatiana Schaffer Gregianini; Renan Rangel Bonamigo
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

8.  Effect of Antifungal-Treated Host Macrophages on Candida glabrata.

Authors:  Hong-Bin Li; Na Li; Shu-Ran Wen; Ming-Yue Qiang; Zheng-Hui Yang; Tian-Xiang Dong; Yu-Ye Li; Yi-Qun Kuang
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-02-18       Impact factor: 2.471

9.  Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates.

Authors:  Laura Bedin Denardi; Débora Alves Nunes Mario; Érico Silva Loreto; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Braz J Microbiol       Date:  2015-03-31       Impact factor: 2.476

10.  Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period.

Authors:  Arnaldo L Colombo; Thais Guimarães; Teresa Sukienik; Alessandro C Pasqualotto; Ricardo Andreotti; Flavio Queiroz-Telles; Simone A Nouér; Marcio Nucci
Journal:  Intensive Care Med       Date:  2014-08-01       Impact factor: 17.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.